Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Haemophilus

Elfamycins have similar in vitro antimicrobial spectra and the activity against Moraxe//a, Pasteure//a, Yersinia Haemophilus Streptococcus Corynebacterium and Neisseria appears to be common (2,23,72). Aurodox (1, R = CH ) (2), azdimycin (8), LL-E19020a(ll, R = H, R = COCH2CgH ), LL-E19020p (11,... [Pg.527]

Diphtheria, Tetanus, and Pertussis. These vacciaes Hi combiaatioa (DTP) have beea routiaely used for active immunization of Hifants and young children sHice the 1940s. The recommended schedule calls for immunizations at 2, 4, and 6 months of age with boosters at 18 months and 4—5 years of age. SHice 1993 these vacciaes have beea available Hi combination with a vacciae that protects agaiast Haemophilus disease, thus providing protectioa agaiast four bacterial diseases Hi oae preparatioa. A booster immunization with diphtheria and tetanus only is recommended once every 10 years after the fifth dose. [Pg.357]

The final vacciae coataHis the two toxoids, as weU as pertussis (whole ceU or aceUular), a buffer, and an adjuvant, ie, a substance that Hicreases the response to an antigen when combHied with the antigen, eg, aluminum. As noted above, the final vacciae can also contain a component that protects against Haemophilus disease. [Pg.357]

Haemophilus influenza serotype b. Three vacciaes are avaUable for immunizing Hifants. Two of these vacciaes are admioistered at 2, 4, and 6 months of age with a booster given at 12—15 months of age, and the third vacciae is admioistered at 2 and 4 months of age with a booster at 12—15 months of age. [Pg.357]

The worldwide market is approximately 3.0 bHHon in sales, with the pediatric portion accounting for about 35%. Basic, required childhood vaccines (DTP, poHo, measles /MMR, BCG, and TT) account for 3640 x 10 doses of this global market. In the United States doses distributed in the pediatric sector have risen from around 45 x 10 in 1982, covering basic, childhood vaccines, to around 75 x 10 in 1993 due primarily to the addition of vaccines for Haemophilus disease, hepatitis B, and a second dose of MMR to the recommended childhood series (144). The majority of vaccines for the U.S. market are... [Pg.361]

CDC, "Progress Toward Elimination of Haemophilus influens e Type b Disease Among Infants and Children— United States, 1993—1994," MMWR, 44(29) (1995). [Pg.363]

Cefuroxime (35) is effective against community-acquired pneumonia in which ampicillin-resistant Haemophilus influence is the probable etiologic agent. Cefoxitin (23) is used to treat mixed aerobic—anaerobic infections including pelvic infections, intra-abdorninal infections, and nosocomial aspiration pneumonia. Cefonicid (31), because of its long half-life has been used in a once-a-day regimen to treat a variety of mild to moderate infections including community-acquired pneumonias, urinary tract infections, and infections of the skin and soft tissue (132,215). [Pg.39]

M ribosomal protection Neisseria, Mycoplasma, Ureaplasma, Haemophilus, Campylobacter, Clostridium, Enterococcus, Staphylococcus, Streptococcus Gardnerella, Kingella, Eikenella, Veillonella, Tusobacterium, Peptostreptococcus Clostridium difficile. Streptococcus pneumoniae... [Pg.182]

There are a number of practical problems involved with using polysaccharides as vaccines as there are frequently too many different chemotypes for it to be practicable to prepare a vaccine. In some cases a limited number of serotypes are the dominant cause of infection and it may then be possible to produce vaccines. A major problem is the poor immune response elicited by polysaccharide antigens, which may in some cases be improved by chemical modification. This is (fie case for vaccines for Haemophilus influenzae type b (a causative agent of meningitis), where the antigenicity of the polysaccharide can be increased by coupling to proteins. [Pg.228]

Haemophilus influenzae type b conjugate and hepatitis B vaccine he -maw-fil-us in-flu-en -zah kon-jew -gate hep -ah-tie -tus bee-vak -seen Lyme disease vaccine (recombinant OspA) lime-vak -seen... [Pg.569]

Haemophilus influenzae type b (Hib) conjugate vaccine. Three Hib conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB or ComVax) is administered at ages 2 and 4 months, a dose at age 6 months is not required. DTaP/Hib combination products should not be used for primary immunization in infants at ages 2, 4 or 6 months, but can be used as boosters following any Hib vaccine. [Pg.575]

Bacterial Macromolecules. I. The Isolation of Deoxyribonucleic Acid from Virulent and Avirulent Strains of Haemophilus pertussis, W. G. Overend, M. Stacey, M. Webb, and J. Ungar, Paper presented at A. G. M., Soc. Gen. Microbiol., April 5, 1950. [Pg.25]

In the cell-wall antigen from Staphylococcus aureus M, taurine is linked as an amide (51) to a 2-acetamido-2-deoxy-D-galactosyluronic residue. l-Threonine and L-glutamic acid are linked as amides to D-glucuronic acid residues in the LPS from Rhodopseudomonas sphaeroides ATCC 17023 and in the capsular polysaccharide from Klebsiella K82, respectively. In the capsular polysaccharide from E. coli K54, L-serine and L-threonine, in the ratio 1 9, are linked to the carboxyl group of a D-glucuronic acid residue. In the capsular polysaccharide from Haemophilus influenzae type d,... [Pg.312]

In different polysaccharides of the teichoic acid type, monosaccharides or oligosaccharides are connected by phosphoric diester linkages. Two examples are the capsular antigens from Neisseria meningitides type A (56) and Haemophilus influenzae type c (57), respectively. Glycerol phosphate... [Pg.315]

Haemophilus influenzae owes its specific name to the fact that it was thought to be the causal organism of influenza (now known to be a virus disease) as it was often isolated in cases ofinfluenza. It is the main cause ofinfantile meningitis and conjunctivitis and is one of the most important causes of chronic bronchitis. [Pg.29]

Virus infections such as influenza and the common cold (in reality 300-400 different strains ofrhinovirus) infect epithelial cells ofthe respiratory tract and nasopharynx, respectively. Release ofthe virus, after lysis ofthe host cells, is to the void rather than to subepithelial tissues. The epithelia is further infected resulting in general degeneration ofthe tracts. Such damage predisposes the respiratory tract to infection with opportunistic pathogens such as Neisseria meningitidis and Haemophilus influenzae. [Pg.82]

In cephalosporins suseeptible to / -lactamases, opening of the y8-lactam ring occurs with concomitant loss of the substituent at (except in cephalexin, where represents H see Fig. 5.4). This is followed by fragmentation of the molecule. Provided that they are not inaetivated by "-laetamases, the cephalosporins generally have a broad spectrum of activity, although there may be a wide variation. Haemophilus influenzae, for example, is partieularly suseeptible to eefuroxime see also Table 5.2. [Pg.97]

Although viral infections are important causes of both otitis media and sinusitis, they are generally self-limiting. Bacterial infections m complicate viral illnesses, and are also primary causes of ear and sinus infections. Streptococcus pneumoniae and Haemophilus influenzae are the commonest bacterial pathogens. Amoxycillin is widely prescribed for these infections since it is microbiologically active, penetrates the middle ear, and sinuses, is well tolerated and has proved effective. [Pg.137]


See other pages where Haemophilus is mentioned: [Pg.459]    [Pg.459]    [Pg.459]    [Pg.295]    [Pg.303]    [Pg.356]    [Pg.356]    [Pg.356]    [Pg.359]    [Pg.27]    [Pg.27]    [Pg.39]    [Pg.45]    [Pg.62]    [Pg.108]    [Pg.182]    [Pg.55]    [Pg.263]    [Pg.269]    [Pg.572]    [Pg.573]    [Pg.11]    [Pg.289]    [Pg.28]    [Pg.399]    [Pg.399]    [Pg.399]    [Pg.633]    [Pg.27]    [Pg.29]    [Pg.138]   
See also in sourсe #XX -- [ Pg.143 ]

See also in sourсe #XX -- [ Pg.46 ]

See also in sourсe #XX -- [ Pg.72 ]

See also in sourсe #XX -- [ Pg.668 ]




SEARCH



Bacteria Haemophilus influenzae

Cefotaxime Haemophilus influenzae

Ceftriaxone Haemophilus influenzae

Escherichia coli Haemophilus influenzae

Genome of Haemophilus influenzae

Haemophilus B conjugate vaccine

Haemophilus B conjugate vaccine Prohibit)

Haemophilus b vaccine

Haemophilus ducreyi

Haemophilus ducreyi Chancroid

Haemophilus ducreyi infections

Haemophilus influenza

Haemophilus influenza strain

Haemophilus influenzae

Haemophilus influenzae Type B

Haemophilus influenzae adverse effects

Haemophilus influenzae antibiotic therapy

Haemophilus influenzae antimicrobials effective against

Haemophilus influenzae capsular

Haemophilus influenzae capsular polysaccharide

Haemophilus influenzae capsular polysaccharide-protein conjugate

Haemophilus influenzae capsular polysaccharide-protein conjugate vaccine

Haemophilus influenzae drug-resistant

Haemophilus influenzae erythromycin activity

Haemophilus influenzae genom

Haemophilus influenzae genome sequence

Haemophilus influenzae infection resistance

Haemophilus influenzae infections

Haemophilus influenzae infections antibiotics

Haemophilus influenzae infections caused

Haemophilus influenzae infections in children

Haemophilus influenzae infections meningitis

Haemophilus influenzae infections pneumonia

Haemophilus influenzae infections sinusitis

Haemophilus influenzae infections treatment

Haemophilus influenzae infections vaccination against

Haemophilus influenzae meningitis

Haemophilus influenzae polysaccharide vaccine

Haemophilus influenzae rates

Haemophilus influenzae respiratory tract infection

Haemophilus influenzae structure

Haemophilus influenzae type

Haemophilus influenzae type b vaccine

Haemophilus influenzae type oligosaccharide-protein conjugates

Haemophilus influenzae upper respiratory tract infection

Haemophilus influenzae vaccine

Haemophilus influenzae, genome

Haemophilus parainfluenzae

Haemophilus pneumoniae

Haemophilus spp

Haemophilus streptococci

Heptoses Haemophilus influenzae

Hib (Haemophilus influenzae type

Neoglycoproteins as Vaccines Against Haemophilus influenzae Type

Oligosaccharide Haemophilus influenzae

Polysaccharides Haemophilus influenzae

Polysaccharides Haemophilus influenzae type

Protein conjugates Haemophilus influenzae type

Vaccinations Haemophilus influenzae

© 2024 chempedia.info